The most common mistake health brands make when building their health marketing funnel is not the one they anticipate. It is not the wrong platform, the wrong budget, or the wrong creative format. It is a borrowed strategy. Most health founders build their funnel the way they built a previous business, or the way they watched a non-regulated competitor do it. Bold claims at the top. Transformation stories in the middle. Urgency at the bottom. That sequence works in categories where the only thing standing between a consumer and a purchase is desire. In regulated health, desire is not the problem. Trust is.
The regulatory environment adds a layer that most marketing frameworks were not designed to handle. The FTC requires that health product claims be backed by competent and reliable scientific evidence. The FDA governs what a brand can and cannot imply about a product’s effect on the body. Meta and Google layer platform-specific restrictions on top of those federal requirements. The result is a category where the conventional playbook does not just underperform — it actively creates risk.
What we have found, working with health founders across regulated categories, is that the brands breaking through are not the ones with the most aggressive funnels. They are the ones that understand what the funnel is actually supposed to do in this specific market, and build accordingly. This is what that looks like.
A health marketing funnel in a regulated market is built around progressive trust, not progressive urgency. Awareness content earns attention through depth, not promises. The middle of the funnel builds credibility before asking for a sale. Conversion happens through evidence — verified customer experiences, transparent quality standards, research references — not through excitement or scarcity. Every stage is governed by FTC substantiation requirements and platform policies that restrict the conventional urgency tactics most DTC funnels rely on.
What follows is a breakdown of where regulated health funnels consistently fail, what the brands that get it right do differently, and why the standard performance metrics most teams are watching are measuring the wrong thing entirely.
There is a pattern we see consistently in regulated health brands that are not hitting their growth numbers. The awareness spend is working. People are finding the brand. And then, somewhere between that first exposure and the purchase decision, they disappear. The conversion rate does not reflect the quality of the product. It reflects a structural problem in how the funnel was built.
The problem is almost always the same: the strategy was designed for a category where trust is assumed, and applied to one where it has to be earned. In most consumer categories, a compelling claim and a strong offer are enough to move someone from awareness to purchase. The stakes are low enough that a consumer will take a chance. A supplement purchased by someone who has already tried four others that did not deliver is not a low-stakes decision. A telehealth subscription chosen by someone who has been let down by vague health promises before is not an impulse buy. These are high-consideration purchases made by skeptical buyers, and the funnel has to be built to match that reality.
The conventional funnel was not. It accelerates desire. It creates urgency. It closes through pressure. Applied to regulated health, that model does not just fail to convert — it actively destroys the credibility that health buyers are specifically looking for. Every exaggerated claim, every unqualified testimonial, every countdown timer reads as a signal that this brand is like every other brand they have already walked away from.
There is also a compliance layer that many brands underestimate until they are dealing with its consequences. The FTC’s health products compliance guidance requires that outcome claims be backed by competent and reliable scientific evidence. Meta prohibits before-and-after imagery. Google applies separate policy requirements for health category advertisers. These are not obstacles to route around. They are markers that show exactly where the conventional playbook breaks down in this category, and why the architecture has to be different.
The brands we see growing in regulated health are not fighting those constraints. They are building around them — and in doing so, differentiating themselves from every competitor still trying to force a non-regulated funnel into a regulated market.
The specific mistake we see most often at the top of a regulated health marketing funnel is not an aggressive claim or a platform-prohibited image. It is an awareness strategy designed to generate attention when what the brand actually needs at this stage is affinity. Those two objectives produce entirely different content — and in regulated health, only one of them scales.
Attention-first TOFU asks: how do we stop the scroll? The conventional answer is a bold promise, a dramatic visual, an emotional hook that shortcuts deliberation. In regulated health, that approach creates two simultaneous problems. It generates reach with an audience that has not yet been given a reason to trust the brand. And it does so with language and imagery that frequently puts the ad account at risk. The result is awareness spend that builds neither relationships nor compliance confidence.
The health brands that run strong TOFU in regulated categories understand something specific about where their audience is when they encounter the brand for the first time. Some are condition-aware and looking for context — the kind of educational content that explains what their bodies are doing, what the research suggests, and what a well-formulated solution might address, without crossing into therapeutic promise language. An article on the role of gut microbiome diversity in digestive comfort, for example, is genuinely useful to someone in that mode without creating any regulatory exposure. Some are ingredient-curious, sophisticated enough to evaluate a mechanism explainer or a research summary, and willing to extend trust to a brand that can explain its formulation rationale clearly. This is the form of long-term brand authority building that compounds over time. Some are broadly health-interested without specific purchase intent, and for them, lifestyle content that connects to the brand’s worldview builds reach without requiring product-adjacent claims at all.
All of it operates on one principle: inform without overpromising. This is not a constraint that limits what the content can do. It is the mechanism by which it earns trust at scale. Educational TOFU also sidesteps Meta’s restrictions on outcome imagery and condition-targeting language by design — not as a workaround, but as a natural consequence of building content that is genuinely useful to the audience first.
The MOFU problem in regulated health is not a content problem. It is a skipping problem. We see it consistently: a brand builds solid awareness campaigns, sets up conversion retargeting, and leaves nothing in between. The warm audience gets one or two product-focused retargeting ads and is expected to convert based on what the TOFU content started. In most categories, a second or third touchpoint is enough. In health, it almost never is.
The consideration-stage health consumer is asking a specific question that product ads cannot answer: how do I know this brand has actually done the work? Not “does the product sound good” — any brand can write good copy. The question is whether the brand can demonstrate it understands the science, respects the audience’s intelligence, and is not going to overpromise. That is a credibility question, and credibility cannot be resolved in an ad. It has to be built in content, over multiple touchpoints, before the ask is made.
The language of MOFU in regulated health is not “you deserve to feel amazing” or “join thousands who transformed their health.” It is “here is what the research suggests,” “here is what we know and what we do not yet know,” and “here is how our formulation reflects that evidence.” This is not modest marketing. It is sophisticated marketing — and with a health-literate audience that has been burned by overstatement before, it converts far better than enthusiasm does.
When we audit MOFU for health brands, the credibility gap almost always comes down to three things that were not built or were built insufficiently:
Formulation transparency. Does the brand understand its own ingredients well enough to explain them? Detailed content that breaks down why specific ingredients were selected, what the research base looks like, and what reasonable expectations a consumer might have gives the audience something substantive to evaluate. This is the kind of material that earns genuine consideration rather than momentary attention.
Third-party credibility signals. Expert interviews, advisory board profiles, and clinical advisors cited by name and credential build trust that standard testimonials cannot replicate on their own. A brand that can name its scientific advisors, link to relevant published research, and explain its manufacturing quality standards is operating at a credibility level most competitors in the category cannot match.
Transparent quality communication. Brands that explain their manufacturing standards, third-party testing process, and quality verification approach signal confidence through evidence rather than assertion. This is especially effective with health-literate consumers who have learned to distinguish a claim from documentation — and who are actively looking for the documentation.
Email sequences are the workhorses of MOFU in a regulated health brand email marketing strategy. A well-structured educational sequence that covers formulation rationale, ingredient evidence, usage guidance, and compliant customer perspectives can move a consideration-stage lead to conversion readiness over a five-to-seven-email window. The key is that each email adds something substantive rather than just pushing toward a purchase. A consumer who feels informed is significantly more likely to convert, and significantly less likely to refund, than one who was persuaded through urgency.
This is the stage where we most often see health brands undo the work that came before it. A brand invests in strong educational TOFU, builds out a thoughtful MOFU sequence, earns genuine consideration from a health-literate audience — and then reaches the close and reverts to tactics borrowed from a different category. Flash sales. Countdown timers. Dramatic transformation testimonials that would not survive FTC scrutiny. In the context of a trust-focused funnel, these do not just create legal exposure. They signal to the consideration-ready consumer that the brand they just spent three touchpoints trusting is actually like every other brand they walked away from.
Effective conversion in a regulated health funnel is not built on urgency. It is built on evidence. Specifically, three forms of evidence that shift the decision from “should I trust this brand?” to “I have enough information to act.”
Compliant testimonials: The FTC endorsement guidelines (16 CFR Part 255) require that testimonials reflect the honest experience of the endorser, disclose any material connections, and not represent atypical results as typical without disclosure. A testimonial that says “I noticed a difference in my energy levels within two weeks” is compliant and specific. A testimonial that says “I completely transformed my health in thirty days” requires substantiation and disclosure. The former closes without legal exposure. The latter creates it. Health brands should conduct testimonial compliance reviews before any testimonial appears in advertising.
Clinical references: If a formulation includes ingredients studied in peer-reviewed research, linking directly to that research at the point of conversion builds confidence without making prohibited claims. A landing page that says “formulated with [ingredient], which has been studied in human clinical trials,” and links to that research, is meaningfully different from one that says “clinically proven to produce [outcome].” The first is factual and compliant. The second requires drug-level substantiation for a supplement.
Transparency as differentiation: Brands that publish Certificates of Analysis, explain their third-party testing process, and make their quality standards explicitly visible convert better in regulated categories. The close becomes a statement of “here is the evidence” rather than “trust us, it works.” Satisfaction guarantees structured correctly, offering a refund if the customer is not satisfied rather than guaranteeing a specific health outcome, signal confidence without creating regulatory exposure.
One of the clearest signals that a health brand has not built a proper regulated marketing funnel is that they treat platform policy as a separate conversation from strategy. It is not. Platform restrictions are not obstacles to navigate around. They are structural features of the environment the funnel operates in — and understanding them precisely is what separates brands that scale from those that run well for three weeks before an account gets flagged.
Meta’s ad policies restrict health and wellness advertising in several significant ways. Before-and-after images are prohibited. Ads cannot imply that viewers have a health condition or emphasize personal distress related to health. Certain categories, including weight loss and specific medical conditions, face additional restrictions and may require LegitScript certification, which applies specifically to online pharmacy and pharmaceutical advertisers, not health and wellness brands broadly. Health supplement brands are subject to Meta’s health and wellness ad policies but do not fall under Meta’s Special Ad Categories (which cover credit, employment, housing, and social issues/elections). They do not go through a formal advertiser certification process. These restrictions apply to the ad creative itself, but a funnel that begins with a restricted ad and drives to an unverified claim on the landing page still represents compliance risk across the full customer journey.
Google Ads requires certification for pharmaceutical manufacturers, online pharmacies, telemedicine providers, and certain other healthcare business types. In July 2025, Google launched a new Restricted Drug Term Personalization Certification for advertisers who want to use personalized targeting tools to reach healthcare professionals with content containing prescription drug terms. As of October 2025, advertisers can use prescription drug terms in ads and on landing pages without certification, but only in limited, non-promotional contexts such as public health content, academic references, or legal notices. Keyword-targeting those terms still requires certification. Content distributed through the Display Network is subject to separate healthcare and medicines policies that restrict certain health claim language in ad copy regardless of the advertiser’s certification status.
The practical implication for a regulated DTC funnel is that platform distribution strategy must be built around what is compliant at each stage. TOFU awareness campaigns on Meta should use educational content formats that do not rely on outcome imagery or condition-targeting. MOFU retargeting should lean on ingredient education, brand credibility signals, and research-backed content. BOFU conversion campaigns should use compliant testimonials, clinical references, and offer framing rather than health outcome promises.
| Funnel stage | Platform approach | Compliant format | What to avoid |
|---|---|---|---|
| TOFU | Broad awareness on Meta and Google Display | Educational articles, ingredient explainers, lifestyle content | Before/after imagery, condition-targeting language, outcome promises |
| MOFU | Retargeting to engaged audiences | Formulation deep dives, expert content, educational email sequences | Unsubstantiated efficacy claims, testimonials without FTC-required disclosures |
| BOFU | Conversion campaigns to warm, education-primed audiences | Compliant testimonials, clinical references, satisfaction guarantees | Outcome guarantees, dramatic transformation language, disease treatment claims |
This is not a creative constraint to manage around. It is a structural advantage to build into the strategy from the start. Brands that construct their DTC health marketing funnel around what the platforms permit can operate at scale without account risk. Brands that push against platform policies for short-term performance tend to face account restrictions precisely when their funnel is gaining momentum.
Claims language is the single most consistent source of compliance errors in regulated health marketing. The distinction between a compliant claim and a prohibited one can be a single word, and that word can determine whether an ad runs or gets pulled, whether a product page passes FDA review or triggers an enforcement letter.
The framework for claims language in a health funnel marketing strategy maps to two categories established by FDA regulation: structure/function claims and disease claims. Structure/function claims describe how a product supports normal physiological functions of the body. Disease claims assert that a product treats, cures, prevents, or mitigates a specific disease or condition. The FDA permits structure/function claims for dietary supplements, subject to the required disclaimer. Disease claims for supplements are not permitted without drug approval, which supplements do not hold.
In practical terms, this distinction creates a vocabulary divide that shows up in every piece of content a health brand produces. Words like “supports,” “helps maintain,” “designed to complement,” “may help support,” and “formulated with ingredients studied for their role in” are on one side of it. Words like “treats,” “cures,” “eliminates,” “heals,” “prevents disease,” and “clinically proven to produce” are on the other. The line between them is not always intuitive, which is why claims language errors accumulate so reliably in health brand funnels where no one is actively maintaining it.
What we have found working across regulated health categories is that prohibited language often sounds more persuasive — and that is exactly why it keeps appearing. “Clinically proven to eliminate fatigue” feels like a stronger conversion lever than “formulated with ingredients studied for their role in energy metabolism.” But the first creates enforcement exposure, and the second, written with precision and confidence, builds more durable trust with the health-literate consumer who is actively discounting anything that sounds overclaimed. The brands that understand this stop treating the claims vocabulary as a legal compliance exercise and start treating it as a conversion advantage.
One practical approach is to let the evidence do the heavy lifting rather than making claims directly. Citing the research that underpins a formulation, and linking to it, is not a health claim. It is a factual statement about existing research that allows the consumer to draw their own informed conclusions. This approach works at every stage of the funnel. At TOFU, frame content around “the research suggests” rather than “research proves.” At MOFU, use “some users report” with appropriate disclosure rather than “users experience.” At BOFU, use “formulated with ingredients that have been studied for [function]” rather than “[product] produces [outcome].” For a deeper look at how claims language applies in advertising specifically, the FTC’s health products compliance guidance is the primary reference.
Standard marketing metrics were designed for funnels built around speed, urgency, and transactional conversion. Click-through rate, cost per click, and ROAS tell you how efficiently ads are driving action. They do not tell you whether the funnel is building the kind of trust that produces retention, referrals, and long-term value in a regulated health category. Optimizing a regulated health funnel against those metrics alone is one of the most reliable ways to produce short-term conversion numbers that look fine and a brand that does not grow.
The signals that actually tell you whether the funnel is working in regulated health are not always the easiest to pull from a dashboard, but they are the most meaningful ones to build toward.
Content engagement depth reveals more about lead quality than click volume does. A consumer who spends four minutes reading a formulation rationale page and follows an internal link to sourcing standards is a fundamentally different prospect than one who clicked an ad and bounced in twelve seconds. These are trust signals, and they belong in any measurement framework built for a regulated DTC marketing strategy.
Email engagement quality inside a MOFU sequence tells you how far along the trust arc each subscriber actually is. Which specific emails they open, which links they click, and whether they are engaging with educational content or only promotional sends reveals segmentation intelligence that aggregate open rate never could. Brands that map educational content engagement to conversion timing consistently find cleaner, lower-refund buyers at the BOFU stage.
Return visit rate before first purchase is one of the clearest indicators of whether MOFU content is doing its job. A health consumer who returns to the site three times before purchasing is signaling that the content was compelling enough to bring them back. A consumer who clicks an ad, lands on a product page, and bounces is signaling that the trust-building infrastructure between those two points was not there.
Conversion quality, not just conversion rate, is the metric that separates a regulated health funnel from a performance campaign. A lower conversion rate from a highly engaged, education-primed audience will typically produce significantly better 90-day retention and lower refund rates than a higher conversion rate driven by urgency. Tracking retention, refund rate, and subscription continuation rate alongside initial conversion rate gives an accurate picture of what the funnel is actually building.
Qualitative feedback closes the loop that quantitative metrics leave open. Health consumers who felt they were given accurate, substantiated information, and who experienced results they were led to reasonably expect, become active brand advocates. NPS and customer survey data reveal whether the funnel is building genuine affinity or optimizing for transactions that do not repeat.
Even well-intentioned health brands make structural errors when building their regulated health marketing funnel. Understanding the most common patterns helps avoid the compliance exposure and performance degradation they cause.
Borrowing tactics from non-regulated categories: The most common error. A health brand observes a competitor in a non-regulated space using aggressive urgency tactics, dramatic testimonials, or bold outcome claims, and copies the approach. The tactics may have worked for the competitor. In a regulated health category, they create compliance risk and erode trust with a health-literate audience that has developed a finely tuned sense for when it is being overpromised to.
Skipping the MOFU entirely: Many health brands invest in awareness campaigns and then go straight to conversion retargeting with no trust-building content in between. The result is a cold audience being asked to make a high-consideration purchase without sufficient credibility signals. MOFU content is not optional in a regulated health brand content strategy. It is the mechanism that makes BOFU conversion possible. Removing it and wondering why conversion rates are low is one of the most predictable performance problems in health DTC marketing.
Using testimonials without compliance review: Testimonials are among the most powerful conversion tools in the funnel for health marketing and among the most regulated. Every testimonial used in advertising must comply with FTC endorsement guidelines, must reflect the honest experience of the endorser, and must be accompanied by appropriate disclosures when the results depicted are not typical. Testimonials pulled directly from reviews without compliance review are a consistent source of enforcement risk. Health brands should have a formal testimonial review process before any customer story appears in ad creative.
Treating platform approval as regulatory compliance: Getting an ad approved by Meta or Google does not mean it complies with FTC or FDA standards. Platform review processes are not regulatory compliance processes. An ad can be approved by a platform and still constitute a violation of FTC advertising guidelines. Health brands need compliance review that operates independently of platform approval, particularly for claims language and testimonial framing.
Building a health DTC marketing funnel without a written claims framework: Every health brand should have a defined internal document that specifies which claim types are permitted at each funnel stage, which are restricted, and which require specific substantiation before use. Without this, every piece of content is evaluated ad hoc, inconsistent language accumulates across the funnel, and claims language errors compound over time into meaningful regulatory and reputational exposure.
A: The primary difference is that trust cannot be assumed. In most DTC categories, a compelling offer and a strong creative is enough to close a first purchase. In regulated health, the consumer has usually been burned before — by overpromised products, by exaggerated testimonials, by claims that did not hold up. The funnel has to do something standard DTC funnels do not: earn credibility before it earns the sale. The regulatory layer — FTC substantiation, FDA structure/function claim rules, platform restrictions at Meta and Google — exists on top of that trust gap, not instead of it. Both have to be designed around, at every stage.
A: The content that performs best on Meta for health brands is content that would be worth consuming even if there were no product at the end of it. Educational video explaining an ingredient mechanism. A carousel walking through what a particular type of research actually found. Lifestyle content that reflects the brand’s worldview without making a product claim. These formats move through Meta’s ad review cleanly because they are not pushing against health category restrictions — they were designed around what those restrictions are protecting in the first place. Direct product awareness ads in health categories consistently underperform by comparison, because one ad cannot bridge a trust gap that took years of bad industry actors to create.
A: The testimonials that hold up under FTC scrutiny are specific, individual, and honest about what they are not claiming. “I noticed a difference in my energy within two weeks” is a compliant testimonial. It describes a real person’s experience without representing it as typical or guaranteed. “I completely transformed my health” requires substantiation or disclosure, and usually gets brands into trouble. The practical rule is: the more dramatic the claim, the more it needs to be treated as a health outcome assertion rather than a personal statement. Material connections — compensation, free product, brand relationship — always require disclosure. A formal testimonial compliance review before any customer story goes into ad creative is not optional in regulated health. It is standard operating procedure.
A: Paid platforms are the hardest place to execute MOFU in regulated health, and the least necessary. Email marketing and organic owned channels are not subject to the same real-time ad policy review, which means the formulation deep dives, advisory board profiles, and research summaries that build consideration-stage credibility can be delivered there without the same creative restrictions. Brands that rely on paid retargeting alone for MOFU in health categories are doing the most compliance-constrained version of this work when they could be doing the most effective version of it instead. A strong owned email channel is not a backup strategy in regulated health. It is the infrastructure that makes the whole funnel work.
A: The line is the word “treats.” Structure/function claims describe what a product does in support of normal body function. Disease claims assert that a product treats, prevents, or cures a condition. “Supports healthy energy levels” is a structure/function claim. “Treats chronic fatigue syndrome” is a disease claim that requires FDA drug approval — which a supplement does not have. The required FDA disclaimer (“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease”) must accompany all structure/function claims in supplement marketing. In practice, the distinction comes down to whether the language implies a therapeutic relationship to a specific disease. When it does, it has crossed the line, regardless of how the claim was phrased.
A: Not through click-through rate or ROAS. What we look at is content engagement depth, return visit rate before first purchase, refund rate in the 30 to 90 day window, and qualitative feedback on whether the brand delivered what it implied it would. These take longer to build than short-term campaign metrics, but they tell you something click volume never can: whether the people buying your product felt they understood what they were buying, and whether their experience after purchase matched what the funnel prepared them to expect. That alignment — between what the funnel communicates and what the product actually does — is what produces retention in regulated health. It is also what makes the brand defensible over time.
A: The FTC is not passive about health product advertising. Recent enforcement actions have targeted brands and individual endorsers for claims that could not meet the competent and reliable scientific evidence standard, and for testimonials that misrepresented typical results without required disclosure. The practical implication is that every claim in the funnel — in ad copy, on landing pages, in email, in testimonials — needs to be able to survive scrutiny against that standard, not just pass a platform review. Platform approval and regulatory compliance are not the same thing. A funnel built around education and evidence-based claims language reduces FTC exposure as a function of how it is built, not as a separate compliance overlay added at the end.
A: Email is where the MOFU work actually gets done for most health brands operating at scale. It is not subject to real-time ad policy review, which means a brand can go significantly deeper on formulation rationale, ingredient research, and quality standards without hitting the creative restrictions that constrain what paid platforms allow at the consideration stage. A five-to-seven email educational sequence can move a subscriber from awareness to purchase confidence in a way that a retargeting ad never could, because it has the time and space to actually build the argument. For regulated health brands, a strong owned email channel is not a secondary channel. It is the one with the most latitude to do what the funnel actually needs done in the middle.
A: Depth over volume, almost always. One well-researched ingredient education page that genuinely answers every question a consideration-stage consumer is likely to have is more effective than five shallow posts that skim the same surface. The highest-leverage investment for a small team is an email sequence: built once, automated, refined over time as you learn what the audience responds to. Five emails covering formulation rationale, key ingredient context, third-party quality validation, a well-framed customer perspective, and an evidence-based close can do the full MOFU trust-building job without requiring ongoing content production. The other thing small teams consistently underestimate is what they already have. Formulation documentation, research references, quality certification language — this is material that already exists in most health brands and has simply never been translated into a format a consumer can engage with. That translation is often the entire MOFU problem.
The health founders we work with most often come to us after a version of the same experience. The funnel is live. The ad spend is committed. The product is genuinely good. And the numbers do not reflect any of that — not because the strategy was wrong in a general sense, but because it was the right strategy for a different category applied to one where it cannot work.
At Beluxe Creative, this is the work we do with health brands every day. Diagnosing where the funnel architecture is creating friction. Building MOFU content that earns consideration before asking for a purchase. Constructing claims language that holds under FTC and FDA scrutiny. Executing at each platform with the specific creative format the policy environment requires. The result is a health marketing funnel that can scale without putting the brand’s advertising access, regulatory standing, or hard-won credibility at risk.
→ Talk to us about your regulated health marketing funnel
Beluxe Creative follows strict sourcing standards. All regulatory references in this article link directly to primary source government and platform policy documents. No third-party summaries of regulatory guidance are cited in place of original sources.
Disclaimer: This content is for informational and educational purposes only. It does not constitute legal or regulatory advice. Regulations governing health product advertising, including FTC and FDA guidelines, evolve over time and vary by product category and jurisdiction. Brands should work with qualified legal and regulatory counsel to verify that their marketing materials comply with all applicable requirements before publishing or distributing any health-related advertising content.
